Immunotherapy in urothelial cancer: to
whom?
Figure adapted from Fakhrejahani et al. Curr Opin Urol 2015
*Immunotherapies under investigation as monotherapy and combination regimens
1. Babjuk et al. Eur Urol 2013; 2. Clinicaltrials.gov. NCT02625961; 3. Clinicaltrials.gov. NCT02632409
4. Witjes et al. Eur Urol 2014; 5. Bellmunt et al. Ann Oncol 2014; 6. Clinicaltrials.gov. NCT02387996
7. Clinicaltrials.gov. NCT02516241; 8. Clinicaltrials.gov. NCT02302807; 9. Clinicaltrials.gov. NCT02603432
Non-muscle
invasive
bladder cancer
(NMIBC)
1,2
Muscle-invasive
bladder cancer
(MIBC)
3–5
Metastatic
bladder cancer
4–9
Low-grade
High-grade*
Neoadjuvant*
Adjuvant*
BCG-refractory*
Cisplatin-
refractory*
Maintenance*
Cisplatin-
ineligible*
2L+
1L
Cisplatin-
eligible*
